Kost C, Benner K, Stockmann A, Linder D, Preissner K T
Haemostasis Research Unit, Kerckhoff-Klinik, Bad Nauheim, Germany.
Eur J Biochem. 1996 Mar 1;236(2):682-8. doi: 10.1111/j.1432-1033.1996.0682d.x.
The adhesion protein vitronectin is associated with extracellular matrices and serves as cofactor for plasminogen-activator inhibitor-1. Limited proteolysis by plasmin converts vitronectin into defined fragments which are detectable at sites of inflammation and angiogenesis. The loss and gain of binding functions of vitronectin fragments for macromolecular ligands was characterized in the present study. The initially generated 61--63-kDa vitronectin-(1--348)-fragment serves as typical binding component for plasminogen and binding function was lost upon carboxypeptidase B treatment indicating the importance of a C-terminal lysine. Complementary binding sites reside in isolated plasminogen kringles 1--3 (designated angiostatin) as deduced from direct binding and ligand blotting experiments. A synthetic vitronectin-(331--348)-peptide from the C-terminus of the 61--63-kDa fragment could mimic plasminogen and angiostatin binding. Also, the immobilized peptide bound tissue plasminogen-activator and mediated plasmin formation, comparable to fibrinogen-derived peptides. The 61--63-kDa vitronectin fragment was indistinguishable in its adhesive properties to intact vitronectin and bound active but not latent plasminogen-activator inhibitor-1. Late plasminolysis of vitronectin resulted in the processing of the N-terminal region of the protein with the generation of 42 kDa/35-kDa fragments that had Gly89 as new N-terminus and that were ineffective in promoting cell adhesion. Thus, at sites of cell-matrix interactions which become proteolytically modified by plasmin during inflammatory and angiogenic processes, vitronectin serves as plasminogen/angiostatin-binding factor. Due to this differential change in functions particularly at sites of deposition in the vascular system or at wound sites vitronectin is considered to be an important morpho-regulatory factor.
黏附蛋白玻连蛋白与细胞外基质相关,作为纤溶酶原激活物抑制剂-1的辅因子。纤溶酶对玻连蛋白进行有限的蛋白水解,可将其转化为特定片段,这些片段在炎症和血管生成部位可被检测到。本研究对玻连蛋白片段与大分子配体结合功能的丧失和获得进行了表征。最初生成的61 - 63 kDa玻连蛋白-(1 - 348)-片段是纤溶酶原的典型结合成分,经羧肽酶B处理后结合功能丧失,表明C末端赖氨酸的重要性。通过直接结合和配体印迹实验推断,互补结合位点存在于分离的纤溶酶原kringles 1 - 3(称为血管抑素)中。来自61 - 63 kDa片段C末端的合成玻连蛋白-(331 - 348)-肽可模拟纤溶酶原和血管抑素的结合。此外,固定化肽结合组织纤溶酶原激活物并介导纤溶酶形成,与纤维蛋白原衍生的肽相当。61 - 63 kDa玻连蛋白片段的黏附特性与完整玻连蛋白无异,可结合活性但不结合潜伏的纤溶酶原激活物抑制剂-1。玻连蛋白的后期纤溶作用导致蛋白质N末端区域的加工,产生42 kDa/35 kDa片段,其新的N末端为Gly89,且在促进细胞黏附方面无效。因此,在炎症和血管生成过程中被纤溶酶进行蛋白水解修饰的细胞-基质相互作用位点,玻连蛋白作为纤溶酶原/血管抑素结合因子。由于功能的这种差异变化,特别是在血管系统沉积部位或伤口部位,玻连蛋白被认为是一种重要的形态调节因子。